Investors News Releases Sign up for email alerts to receive company and investor updates News Releases Investor Relations Investor Relations News Releases Presentations & Events Common Stock Information Stock Quote & Chart Analyst Coverage SEC Filings Corporate Governance Overview Board of Directors Committee Composition Management Team Annual Reports News Releases Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Sep 12 2018 Cyclacel Pharmaceuticals Appoints Robert J. Spiegel, M.D. to Board of Directors Sep 10 2018 Cyclacel Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Sapacitabine With Olaparib in BRCA Mutant Breast Cancer Aug 29 2018 Cyclacel Pharmaceuticals to Present at the 20th Annual H.C. Wainwright Global Investment Conference Aug 09 2018 Cyclacel Pharmaceuticals Reports Second Quarter 2018 Financial Results Aug 01 2018 Cyclacel Pharmaceuticals to Release Second Quarter 2018 Financial Results May 14 2018 Cyclacel Pharmaceuticals Reports First Quarter 2018 Financial Results May 08 2018 Cyclacel Pharmaceuticals to Release First Quarter 2018 Financial Results Apr 17 2018 Cyclacel’s CYC065 CDK Inhibitor Demonstrates Synergy With Venetoclax By Dual Targeting Of Chronic Lymphocytic Leukemia Apr 16 2018 Cyclacel Announces Presentation of Phase 1 Clinical Data for CDK Inhibitor CYC065 at AACR 2018 Annual Meeting Mar 28 2018 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results Mar 21 2018 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2017 Financial Results Mar 15 2018 Phase 1 Clinical Data With Cyclacel’s CYC065 CDK Inhibitor Have Been Selected for Oral Presentation at AACR 2018 Annual Meeting Mar 06 2018 Cyclacel Pharmaceuticals to Present at the 30th Annual ROTH Conference Feb 21 2018 Cyclacel Announces Notice of Grant of New European Patent Covering Sapacitabine Pharmaceutical Formulations Feb 06 2018 Cyclacel Pharmaceuticals to Present at the 2018 BIO CEO & Investor Conference Jan 24 2018 Cyclacel Pharmaceuticals to Present at the Noble Capital Markets Investor Conference Jan 09 2018 Cyclacel Reviews 2017 Achievements and Announces Key Business Objectives for 2018 Dec 12 2017 Cyclacel Announces Presentation of Results From Phase 3 Seamless Study at Ash Annual Meeting Nov 09 2017 Cyclacel Pharmaceuticals Reports Third Quarter 2017 Financial Results Nov 02 2017 Cyclacel Pharmaceuticals to Release Third Quarter 2017 Financial Results Nov 01 2017 Cyclacel Pharmaceuticals Announces That Full Results From the Phase 3 Seamless Trial Have Been Selected for Oral Presentation at ASH 2017 Annual Meeting Sep 21 2017 Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2017 Healthcare Conference Sep 08 2017 Cyclacel Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Global Investment Conference Aug 09 2017 Cyclacel Pharmaceuticals Reports Second Quarter 2017 Financial Results Aug 07 2017 Cyclacel Announces Selection of Recommended Phase 2 Dose for CYC065 and Evidence of Durable Target Engagement and Mcl-1 Biomarker Suppression Pagination First page « first Previous page ‹ previous … Page 2 Page 3 Page 4 Page 5 Current page 6 Page 7 Page 8 Page 9 Page 10 … Next page next › Last page last » Toolkit Email AlertsRSS FeedsPrint Page
News Releases Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Sep 12 2018 Cyclacel Pharmaceuticals Appoints Robert J. Spiegel, M.D. to Board of Directors Sep 10 2018 Cyclacel Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Sapacitabine With Olaparib in BRCA Mutant Breast Cancer Aug 29 2018 Cyclacel Pharmaceuticals to Present at the 20th Annual H.C. Wainwright Global Investment Conference Aug 09 2018 Cyclacel Pharmaceuticals Reports Second Quarter 2018 Financial Results Aug 01 2018 Cyclacel Pharmaceuticals to Release Second Quarter 2018 Financial Results May 14 2018 Cyclacel Pharmaceuticals Reports First Quarter 2018 Financial Results May 08 2018 Cyclacel Pharmaceuticals to Release First Quarter 2018 Financial Results Apr 17 2018 Cyclacel’s CYC065 CDK Inhibitor Demonstrates Synergy With Venetoclax By Dual Targeting Of Chronic Lymphocytic Leukemia Apr 16 2018 Cyclacel Announces Presentation of Phase 1 Clinical Data for CDK Inhibitor CYC065 at AACR 2018 Annual Meeting Mar 28 2018 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results Mar 21 2018 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2017 Financial Results Mar 15 2018 Phase 1 Clinical Data With Cyclacel’s CYC065 CDK Inhibitor Have Been Selected for Oral Presentation at AACR 2018 Annual Meeting Mar 06 2018 Cyclacel Pharmaceuticals to Present at the 30th Annual ROTH Conference Feb 21 2018 Cyclacel Announces Notice of Grant of New European Patent Covering Sapacitabine Pharmaceutical Formulations Feb 06 2018 Cyclacel Pharmaceuticals to Present at the 2018 BIO CEO & Investor Conference Jan 24 2018 Cyclacel Pharmaceuticals to Present at the Noble Capital Markets Investor Conference Jan 09 2018 Cyclacel Reviews 2017 Achievements and Announces Key Business Objectives for 2018 Dec 12 2017 Cyclacel Announces Presentation of Results From Phase 3 Seamless Study at Ash Annual Meeting Nov 09 2017 Cyclacel Pharmaceuticals Reports Third Quarter 2017 Financial Results Nov 02 2017 Cyclacel Pharmaceuticals to Release Third Quarter 2017 Financial Results Nov 01 2017 Cyclacel Pharmaceuticals Announces That Full Results From the Phase 3 Seamless Trial Have Been Selected for Oral Presentation at ASH 2017 Annual Meeting Sep 21 2017 Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2017 Healthcare Conference Sep 08 2017 Cyclacel Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Global Investment Conference Aug 09 2017 Cyclacel Pharmaceuticals Reports Second Quarter 2017 Financial Results Aug 07 2017 Cyclacel Announces Selection of Recommended Phase 2 Dose for CYC065 and Evidence of Durable Target Engagement and Mcl-1 Biomarker Suppression Pagination First page « first Previous page ‹ previous … Page 2 Page 3 Page 4 Page 5 Current page 6 Page 7 Page 8 Page 9 Page 10 … Next page next › Last page last »
Sep 10 2018 Cyclacel Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Sapacitabine With Olaparib in BRCA Mutant Breast Cancer
Aug 29 2018 Cyclacel Pharmaceuticals to Present at the 20th Annual H.C. Wainwright Global Investment Conference
Apr 17 2018 Cyclacel’s CYC065 CDK Inhibitor Demonstrates Synergy With Venetoclax By Dual Targeting Of Chronic Lymphocytic Leukemia
Apr 16 2018 Cyclacel Announces Presentation of Phase 1 Clinical Data for CDK Inhibitor CYC065 at AACR 2018 Annual Meeting
Mar 15 2018 Phase 1 Clinical Data With Cyclacel’s CYC065 CDK Inhibitor Have Been Selected for Oral Presentation at AACR 2018 Annual Meeting
Feb 21 2018 Cyclacel Announces Notice of Grant of New European Patent Covering Sapacitabine Pharmaceutical Formulations
Dec 12 2017 Cyclacel Announces Presentation of Results From Phase 3 Seamless Study at Ash Annual Meeting
Nov 01 2017 Cyclacel Pharmaceuticals Announces That Full Results From the Phase 3 Seamless Trial Have Been Selected for Oral Presentation at ASH 2017 Annual Meeting
Sep 08 2017 Cyclacel Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Global Investment Conference
Aug 07 2017 Cyclacel Announces Selection of Recommended Phase 2 Dose for CYC065 and Evidence of Durable Target Engagement and Mcl-1 Biomarker Suppression
